AAAAAA
Results:
1-14
|
Results: 14
Authors:
Bennett, CL
Hynes, D
Godwin, J
Stinson, TJ
Golub, RM
Appelbaum, FR
Citation: Cl. Bennett et al., Economic analysis of granulocyte colony stimulating factor as adjunct therapy for older patients with acute myelogenous leukemia (AML): Estimates from a Southwest Oncology Group clinical trial, CANCER INV, 19(6), 2001, pp. 603-610
Authors:
Bennett, CL
Stinson, TJ
Laver, JH
Bishop, MR
Godwin, JE
Tallman, MS
Citation: Cl. Bennett et al., Cost analyses of adjunct colony stimulating factors for acute leukemia: Can they improve clinical decision making, LEUK LYMPH, 37(1-2), 2000, pp. 65-70
Authors:
Knox, KS
Adams, JR
Djulbegovic, B
Stinson, TJ
Tomori, C
Bennett, CL
Citation: Ks. Knox et al., Reporting and dissemination of industry versus non-profit sponsored economic analyses of six novel drugs used in oncology, ANN ONCOL, 11(12), 2000, pp. 1591-1595
Authors:
Bennett, CL
Stinson, TJ
Citation: Cl. Bennett et Tj. Stinson, Comparing cost-effectiveness analyses for the clinical oncology setting: The example of the Gynecologic Oncology Group 111 trial, CANCER INV, 18(3), 2000, pp. 261-268
Authors:
Bennett, CL
Stinson, TJ
Vogel, V
Robertson, L
Leedy, D
O'Brien, P
Hobbs, J
Sutton, T
Ruckdeschel, JC
Chirikos, TN
Weiner, RS
Ramsey, MM
Wicha, MS
Citation: Cl. Bennett et al., Evaluating the financial impact of clinical trials in oncology: Results from a pilot study from the association of American Cancer Institutes/Northwestern University Clinical Trials Costs and Charges Project, J CL ONCOL, 18(15), 2000, pp. 2805-2810
Authors:
Stinson, TJ
Adams, JR
Bishop, MR
Kruse, S
Tarantolo, S
Bennett, CL
Citation: Tj. Stinson et al., Economic analysis of a phase III study of G-CSF vs placebo following allogeneic blood stem cell transplantation, BONE MAR TR, 26(6), 2000, pp. 663-666
Authors:
Bennett, CL
Stinson, TJ
Lane, D
Amylon, M
Land, VJ
Laver, JH
Citation: Cl. Bennett et al., Cost analysis of filgrastim for the prevention of neutropenia in pediatricT-cell leukemia and advanced lymphoblastic lymphoma: A case for prospective economic analysis in cooperative group trials, MED PED ONC, 34(2), 2000, pp. 92-96
Authors:
Bennett, CL
Stinson, TJ
Tallman, MS
Stadtmauer, EA
Marsh, RW
Friedenberg, W
Lazarus, HM
Kaminer, L
Golub, RM
Rowe, JM
Citation: Cl. Bennett et al., Economic analysis of a randomized placebo-controlled phase III study of granulocyte macrophage colony stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia, ANN ONCOL, 10(2), 1999, pp. 177-182
Authors:
Stinson, TJ
Calhoun, E
Yang, T
Lurain, JR
Bennett, CL
Citation: Tj. Stinson et al., Cost analysis of second-line therapies for platinum-refractory ovarian cancer: Reimbursement dilemmas for medicare patients, CANCER INV, 17(8), 1999, pp. 559-565
Authors:
Bennett, CL
Waters, TM
Stinson, TJ
Almagor, O
Pavletic, ZS
Tarantolo, SR
Bishop, MR
Citation: Cl. Bennett et al., Valuing clinical strategies early in development: a cost analysis of allogeneic peripheral blood stem cell transplantation, BONE MAR TR, 24(5), 1999, pp. 555-560
Authors:
Friedberg, M
Saffran, B
Stinson, TJ
Nelson, W
Bennett, CL
Citation: M. Friedberg et al., Evaluation of conflict of interest in economic analyses of new drugs used in oncology, J AM MED A, 282(15), 1999, pp. 1453-1457
Authors:
Bennett, CL
Stinson, TJ
Yang, T
Lurain, JR
Citation: Cl. Bennett et al., The effect of reimbursement policies on the management of Medicare patients with refractory ovarian cancer, SEMIN ONCOL, 26(1), 1999, pp. 40-45
Authors:
Bennett, CL
Stinson, TJ
Citation: Cl. Bennett et Tj. Stinson, Does reimbursement affect physician decision making?, CANC TREAT, 102, 1999, pp. 137-149
Authors:
Bennett, CL
Stinson, TJ
Citation: Cl. Bennett et Tj. Stinson, Economic, public health, and policy implications of hematopoietic growth factors, high-dose chemotherapy, and stem cell rescue, CLINICAL APPLICATIONS OF CYTOKINES AND GROWTH FACTORS, 1999, pp. 150-158
Risultati:
1-14
|